Is the anti-Human CTLA4 therapeutic antibody Ticilimumab suitable for use in Western blotting?

Yes, the anti-Human CTLA4 therapeutic antibody Ticilimumab (TAB-206) is suitable for use in Western blotting. It provides specific binding to CTLA4, allowing for reliable detection in Western blot assays.

What are the storage recommendations for the anti-Human CTLA4 therapeutic antibody Ticilimumab?

The recommended storage condition for the anti-Human CTLA4 therapeutic antibody Ticilimumab (TAB-206) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

Can the anti-Human CTLA4 therapeutic antibody Ticilimumab be used in immunoprecipitation assays?

Yes, the anti-Human CTLA4 therapeutic antibody Ticilimumab (TAB-206) can be used in immunoprecipitation assays. It provides specific binding to CTLA4, enabling the successful precipitation of the target protein from complex mixtures.

Is the anti-Human CTLA4 therapeutic antibody Ticilimumab effective in ELISA applications?

Yes, the anti-Human CTLA4 therapeutic antibody Ticilimumab (TAB-206) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of CTLA4.

What is the optimal dilution for using the anti-Human CTLA4 therapeutic antibody Ticilimumab in immunofluorescence?

The optimal dilution for using the anti-Human CTLA4 therapeutic antibody Ticilimumab (TAB-206) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

Anti-Human CTLA4 Recombinant Antibody (Ticilimumab (Tremelimumab))

CAT#: TAB-206

Recombinant monoclonal antibody to CTLA4. Tremelimumab (formerly ticilimumab, CP-675,206) is a fully human IgG2 monoclonal antibody, undergoing human trials for the treatment of cancer.

Published Data Tested Data Gene Expression

Figure 1 Binding profiles of ipilimumab-scFv/CTLA-4 and tremelimumab-scFv/CTLA-4 measured by SPR.

CTLA-4 was immobilized on the chip while serially diluted (A) ipilimumab-scFv or (B) tremelimumab-scFv with concentrations ranging from 6.25 nM to 200 nM were then flowed through the chip and the response units were measured.

He, M., Chai, Y., Qi, J., Zhang, C. W., Tong, Z., Shi, Y., ... & Gao, G. F. (2017). Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget, 8(40), 67129.

Figure 2 Modulation of CTLA4 and phosphoprotein expression in monocytes exposed ex vivo to tremelimumab.

Monocytes were cultured in increasing concentrations of tremelimumab for 48 hours, after which were analyzed for intracellular flow cytometry. Data is presented as fold change from the baseline mean fluorescence intensity (MFI) at increasing concentrations of tremelimumab (0, 0.1, 1. 10. 15 and 100 mg/ml) presented in a semilogarithmic plot. Red triangles represent monocytes samples obtained from three patients with metastatic melanoma (MD: melanoma donors); black circles are results from monocytes analyzed from five healthy subjects (HD: healthy donors). a) Intracellular CTLA4 expression; b) pp38(pT180/pY182); c) pErk1/2 (T202/204); d) pAkt (pT308); e) pSTAT1(pY701); f) pSTAT3 (pY705); g) pSTAT5 (Y694); h) pSTAT6 (Y641). **p<0.01; ***p<0.001.

Comin-Anduix, B., Sazegar, H., Chodon, T., Matsunaga, D., Jalil, J., von Euw, E., ... & Koya, R. C. (2010). Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PloS one, 5(9), e12711.

Figure 3 Immune response against HCV antigens after tremelimumab.

(A) IFN-c producing T lymphocytes against HCV antigens were evaluated by ELISPOT assays at different time points after treatment. Antigens used were recombinant core, NS3, NS4, and NS5 proteins, and peptide pools spanning the whole HCV polyprotein. Results represent mean + SEM of spot forming cells (SFC). For peptides, values correspond to the sum of the different pools encompassed in each protein. (p <0.05 compared to day 0). (B) Representative example of anti-HCV responses obtained in patients B and F.

Sangro, B., Gomez-Martin, C., de la Mata, M., Iñarrairaegui, M., Garralda, E., Barrera, P., ... & Lasarte, J. J. (2013). A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. Journal of Hepatology, 59(1), 81-88.

Figure 4 Effect of tremelimumab on the suppressive activity of Tregs in vitro.

CD4+ T cells were positively selected from PBMC samples using CD4 microbeads. CD4+ T cells were labeled with antibodies and used to sort CD4+ CD25+ CD127− Tregs and CD4+ CD25− CD127+ Teff by FACSAria. Tregs and Teff were cultured in triplicate wells alone or together at the ratios indicated with HLA-DR+ cells as APCs and anti-CD3/28 antibodies in the absence or presence of 15 μg/ml tremelimumab. Proliferation was measured by tritiated thymidine and reported as CPM (A). The percent suppression of Teff proliferation by Tregs was also determined (B). Data shown are derived from one donor and representative experiments from 3 different donors.

Khan, S., Burt, D. J., Ralph, C., Thistlethwaite, F. C., Hawkins, R. E., & Elkord, E. (2011). Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clinical Immunology, 138(1), 85-96.

Figure 5 Representative immunohistochemistry of inspiratory muscles at autopsy, 66 days after tremelimumab-durvalumab treatment.

Hematoxylin and eosin (H&E) sections show inflammatory myopathy in the diaphragm and intercostal muscles without rimmed vacuoles and without perifascicular atrophy, consistent with polymyositis. A mononuclear infiltrate is present which invades otherwise normal myofibers and completely effaces the background muscle fiber architecture in some areas. ATPase shows intense staining in small fibers compared to surrounding lighter, normal sized fibers in preserved areas of muscle, indicative of type II fiber atrophy. Trichrome shows mildly increased connective tissue, but shows no rimmed vacuoles, rods, or other inclusions. T cell co-receptor staining (CD3, CD4, CD8) revealed a mixed T-cell infiltrate which often completely effaced the myofascicular architecture. CD68 highlights necrotic myofibers scattered within the larger inflammatory infiltrate. PD-L1 expression was observed in blood vessels of dying muscle. Weak CTLA-4 expression was detected in necrotic myofibers. All images are 100× magnification.

John, S., Antonia, S. J., Rose, T. A., Seifert, R. P., Centeno, B. A., Wagner, A. S., & Creelan, B. C. (2017). Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab-durvalumab treatment. Journal for immunotherapy of cancer, 5(1), 54.

❮

❯

SDS-PAGE

Figure 1 Anti-Human CTLA4 Antibody (TAB-206) in SDS-PAGE

SDS-PAGE analysis of TAB-206 in non-reduced (lane 1, 2.5ug) and reduced (lane 2, 2.5ug) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.

SEC-HPLC

Figure 2 Anti-Human CTLA4 Antibody (TAB-206) in HPLC

The purity of TAB-206 was greater than 95% as determined by SEC-HPLC.

❮

❯

RNA Expression Figure 1 RNA cell line category: Cell line enhanced (Karpas-707, SK-MEL-30, U-266/70, U-266/84)

Cell lines ordered by descending RNA expression order.

* Image credit: Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000163599-CTLA4

❮

❯

Specifications

Immunogen
Human CTLA-4.

Host Species
Human

Derivation
Human

Type
IgG2

Specificity
Tested positive against native human antigen.

Species Reactivity
Human

Applications
WB, IF, IP, Neut, FuncS, ELISA, FC

CAS
745013-59-6

Generic Name
Ticilimumab (= tremelimumab)

UNII
QEN1X95CIX

MW
146.380472 kDa

Product Property

Purity
>95%, by SDS-PAGE with silver staining, under reducing conditions.

Storage
Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.

Applications

Application Notes
The CTLA4 antibody has been reported in applications of SPR, FC, ELISPOT, Activ, IHC.

Target

Alternative Names
Ticilimumab (= tremelimumab);745013-59-6;ticilimumab;CP-675;206;Ticilimumab;CP-675;206;CTLA4;cytotoxic T-lymphocyte-associated protein 4;celiac disease 3 , CELIAC3;cytotoxic T-lymphocyte protein 4;CD;CD28;CD152;GSE;ICOS;CD152 isoform;celiac disease 3;cyto

Gene ID
1493

UniProt ID
P16410

REVIEWS AND Q&AS CITATIONS RESOURCES DOWNLOADS RELATED PRODUCTS

Inquiry

Navs

Customer Review

There are currently no Customer reviews or questions for TAB-206. Click the button above to contact us or submit your feedback about this product.

Breast cancer biomarkers at key points during disease progression

Emily Roberts
12.Sep,23

Ideal for CTLA4 Research

The Anti-Human CTLA4 Therapeutic Antibody (Ticilimumab) has been excellent for our CTLA4 studies. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

Brian Anderson
21.Oct,22

Effective in Immunoassays

We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for CTLA4 is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Jessica Moore
17.May,21

Consistent and High-Quality

This antibody has proven to be consistent and high-quality in our assays. The reproducible results and strong affinity for CTLA4 have significantly improved our experiments, making it a crucial part of our research toolkit. The consistent performance has greatly enhanced our data quality.

Q&As

Is the anti-Human CTLA4 therapeutic antibody Ticilimumab suitable for use in Western blotting?

A: Yes, the anti-Human CTLA4 therapeutic antibody Ticilimumab (TAB-206) is suitable for use in Western blotting. It provides specific binding to CTLA4, allowing for reliable detection in Western blot assays.
What are the storage recommendations for the anti-Human CTLA4 therapeutic antibody Ticilimumab?

A: The recommended storage condition for the anti-Human CTLA4 therapeutic antibody Ticilimumab (TAB-206) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.
Can the anti-Human CTLA4 therapeutic antibody Ticilimumab be used in immunoprecipitation assays?

A: Yes, the anti-Human CTLA4 therapeutic antibody Ticilimumab (TAB-206) can be used in immunoprecipitation assays. It provides specific binding to CTLA4, enabling the successful precipitation of the target protein from complex mixtures.
Is the anti-Human CTLA4 therapeutic antibody Ticilimumab effective in ELISA applications?

A: Yes, the anti-Human CTLA4 therapeutic antibody Ticilimumab (TAB-206) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of CTLA4.
What is the optimal dilution for using the anti-Human CTLA4 therapeutic antibody Ticilimumab in immunofluorescence?

A: The optimal dilution for using the anti-Human CTLA4 therapeutic antibody Ticilimumab (TAB-206) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

Wiese, Teresa, et al. "Inhibition of acid sphingomyelinase increases regulatory T cells in humans." Brain Communications 3.2 (2021): fcab020. https://doi.org/10.1093/braincomms/fcab020

This study investigated the impact of pharmacological inhibition of acid sphingomyelinase (ASM) on regulatory T cells (Tregs) in humans. The researchers aimed to determine whether ASM inhibitors could increase the frequency of Tregs among CD4+ T cells. The study utilized both in vitro experiments with human peripheral blood mononuclear cells (PBMCs) and an observational clinical trial with patients suffering from major depression. The results demonstrated that ASM inhibition with antidepressants like sertraline increased Treg frequencies in vitro and in patients treated with these antidepressants, indicating the potential of ASM inhibitors as immunomodulatory agents.
Creative Biolabs provided the anti-CTLA-4 monoclonal antibody, tremelimumab (Cat#: TAB-206), which was used to investigate the role of CTLA-4 in Treg frequency modulation. This antibody was crucial for determining that ASM inhibition increased Treg frequencies through enhanced CD28 co-stimulation. By blocking CTLA-4, the researchers were able to show that the increase in Treg frequencies required CD28 co-stimulation, highlighting the specific pathways through which ASM inhibitors affect Treg populations. The provision of tremelimumab enabled the detailed analysis of the mechanisms underlying Treg modulation in response to ASM inhibition, significantly contributing to the study's findings.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-206, RRID: AB_3111873)

Copy citation

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Related Diseases

Rheumatoid Arthritis

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

Datasheet - TAB-206.pdf

MSDS

MSDS - TAB-206.pdf

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Lot Number:

Protocol & Troubleshooting

Immunofluorescence (IF)

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "Ticilimumab (= Tremelimumab)"

Afuco™ Anti-CTLA4 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-206)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CTLA4. It is a fully human IgG2 monoclonal antibody, undergoing human trials for the treatment of cancer.

See other products for "CTLA4"

Select a product category from the dropdown menu below to view related products.

CAT	Product Name	Application	Type
DrMAB-986	Recombinant Mouse Anti-Human CTLA4 Antibody F(ab')₂ Fragment, clone ANC152.2/8H5	FC, EIA, FX, Bios	F(ab')2
DrMAB-987	Mouse Anti-CTLA4 Recombinant Antibody (clone ANC152.2/8H5); Fab Fragment	FC, ELISA	Mouse Fab
HPAB-0749LY-F(E)	Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-0749LY-F(E))	FuncS, ELISA	Human Fab
HPAB-0750LY-F(E)	Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-0750LY-F(E))	FuncS, ELISA	Human Fab
HPAB-0751LY-F(E)	Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-0751LY-F(E))	FuncS, ELISA	Human Fab

CAT	Product Name	Application	Type
TAB-067	Anti-Human CTLA4 Recombinant Antibody (TAB-067)	WB, FuncS, IF, Neut, ELISA, FC, IP	IgG1 - kappa

CAT	Product Name	Application
AGTO-G015E	Anti-CTLA4 immunotoxin (scFv)-PE	Cytotoxicity assay, Function study
AGTO-G015S	Anti-CTLA4 immunotoxin (scFv)-Sap	Cytotoxicity assay, Function study
AGTO-G015M	Anti-CTLA4 immunotoxin (scFv)-Mel	Cytotoxicity assay, Function study

CAT	Product Name	Application	Type
TAB-195CL	Mouse Anti-CTLA4 Recombinant Antibody (TAB-195CL)	ELISA	Mouse IgG

CAT	Product Name	Application	Type
TAB-085MZ	Anti-Human CTLA4 Recombinant Antibody (TGN2122.C)	ELISA, FC	Chimeric antibody (mouse/human)
TAB-086MZ	Anti-Human CTLA4 Recombinant Antibody (TGN2422.C)	ELISA, FC	Chimeric antibody (mouse/human)
TAB-085MZ-S(P)	Anti-Human CTLA4 Recombinant Antibody scFv Fragment (TGN2122.C)	ELISA, FC	Chimeric antibody (mouse/human)
TAB-086MZ-S(P)	Anti-Human CTLA4 Recombinant Antibody scFv Fragment (TGN2422.C)	ELISA, FC	Chimeric antibody (mouse/human)
TAB-085MZ-F(E)	Anti-Human CTLA4 Recombinant Antibody Fab Fragment (TGN2122.C)	ELISA, FC	Chimeric antibody (mouse/human)

CAT	Product Name	Application	Type
TAB-087MZ	Mouse Anti-CTLA4 Recombinant Antibody (TAB-087MZ)	ELISA	Mouse IgG
TAB-087MZ-S(P)	Mouse Anti-CTLA4 Recombinant Antibody; scFv Fragment (TAB-087MZ-S(P))	ELISA	Mouse scFv
TAB-089MZ-S(P)	Mouse Anti-CTLA4 Recombinant Antibody; scFv Fragment (TAB-089MZ-S(P))	ELISA	Mouse scFv
TAB-090MZ-S(P)	Mouse Anti-CTLA4 Recombinant Antibody; scFv Fragment (TAB-090MZ-S(P))	ELISA	Mouse scFv
TAB-093MZ-S(P)	Anti-Human CTLA4 Recombinant Antibody scFv Fragment (Mu-26B)	ELISA

CAT	Product Name	Application	Type
TAB-083MZ-S(P)	Anti-Human CTLA4 Recombinant Antibody scFv Fragment (TGN2122.H)	ELISA, FC	Humanized antibody
TAB-084MZ-S(P)	Anti-Human CTLA4 Recombinant Antibody scFv Fragment (TGN2422.H)	ELISA, FC	Humanized antibody
TAB-088MZ-S(P)	Human Anti-CTLA4 Recombinant Antibody; scFv Fragment (TAB-088MZ-S(P))	ELISA	Human scFv
TAB-091MZ-S(P)	Human Anti-CTLA4 Recombinant Antibody; scFv Fragment (TAB-091MZ-S(P))	ELISA	Human scFv
TAB-092MZ-S(P)	Human Anti-CTLA4 Recombinant Antibody; scFv Fragment (TAB-092MZ-S(P))	ELISA	Human scFv

CAT	Product Name	Application	Type
MOB-1734MZ	Recombinant Mouse Anti-Human CTLA4 Antibody (clone COJ4)	FC, ICC, IHC-Fr	Mouse antibody
MOB-006LC	Hamster Anti-Ctla4 Recombinant Antibody (clone YC082)	ELISA, FC	Hamster IgG
HPAB-1660LY	Mouse Anti-CTLA4 Recombinant Antibody (HPAB-1660LY)	FC, Block, ELISA	Mouse IgG
FN-003CQ	Mouse Anti-CTLA4 Recombinant Antibody (clone ANC152.2/8H5)	ELISA, FC, Block	Mouse IgG1, κ
HPAB-0270-YJ	Human Anti-CTLA4 Recombinant Antibody (clone CBC46YJ)	ELISA, FC, Block	Human IgG

CAT	Product Name	Application	Type
NEUT-567CQ	Mouse Anti-CTLA4 Recombinant Antibody (NEUT-567CQ)	FC, FuncS, Neut, IP, WB	Mouse IgG2a, κ
NEUT-569CQ	Mouse Anti-CTLA4 Recombinant Antibody (clone AS32)	WB, Neut	Mouse IgG1
NEUT-570CQ	Human Anti-CTLA4 Recombinant Antibody (clone YC030)	Neut	Human IgG1, κ
NEUT-572CQ	Hamster Anti-Ctla4 Recombinant Antibody (clone UC10-4B9)	FC, Block, ELISA, IP	Hamster IgG
NEUT-573CQ	Rat Anti-Ctla4 Recombinant Antibody (clone 63828)	WB, FC, Neut	Rat IgG2a

CAT	Product Name	Application	Type
NEUT-568CQ	Mouse Anti-CTLA4 Recombinant Antibody (clone L3D10)	FC, Block	Mouse IgG1, κ
NEUT-571CQ	Mouse Anti-CTLA4 Recombinant Antibody (clone BN13)	Block, FC	Mouse IgG2a
NEUT-577CQ	Hamster Anti-Ctla4 Recombinant Antibody (clone MAB0835)	Block, FC	Hamster IgG
NEUT-578CQ	Hamster Anti-Ctla4 Recombinant Antibody (NEUT-578CQ)	Block	Hamster IgG
NEUT-579CQ	Hamster Anti-Ctla4 Recombinant Antibody (clone 9H10)	FC, Block	Hamster IgG

CAT	Product Name	Application	Type
MOR-0855	Hi-Affi™ Rabbit Anti-CTLA4 Recombinant Antibody (clone DS855AB)	WB	Rabbit IgG

CAT	Product Name	Application	Type
HPAB-N0343-YC-S(P)	Human Anti-CTLA4 Recombinant Antibody; scFv Fragment (HPAB-N0343-YC-S(P))	FC, ELISA	Human scFv
HPAB-0752LY-S(P)	Human Anti-CTLA4 Recombinant Antibody; scFv Fragment (HPAB-0752LY-S(P))	FuncS, ELISA	Human scFv
HPAB-0753LY-S(P)	Human Anti-CTLA4 Recombinant Antibody; scFv Fragment (HPAB-0753LY-S(P))	FuncS, ELISA	Human scFv
HPAB-0754LY-S(P)	Human Anti-CTLA4 Recombinant Antibody; scFv Fragment (HPAB-0754LY-S(P))	FuncS, ELISA	Human scFv
HPAB-0755LY-S(P)	Human Anti-CTLA4 Recombinant Antibody; scFv Fragment (HPAB-0755LY-S(P))	FuncS, ELISA	Human scFv

CAT	Product Name	Application	Type
AFC-TAB-067	Afuco™ Anti-CTLA4 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-067)	FuncS, IF, Neut, ELISA, FC	ADCC enhanced antibody
AFC-TAB-206	Afuco™ Anti-CTLA4 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-206)	IF, IP, Neut, FuncS, ELISA	ADCC enhanced antibody

CAT	Product Name	Application	Type
HPAB-AP863-YC	Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP863-YC)	ELISA, Block	Camel VHH
HPAB-AP864-YC	Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP864-YC)	ELISA, Block	Camel VHH
HPAB-AP865-YC	Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP865-YC)	ELISA, Block	Camel VHH
HPAB-AP866-YC	Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP866-YC)	ELISA, Block	Camel VHH
HPAB-AP867-YC	Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP867-YC)	ELISA, Block	Camel VHH

CAT	Product Name	Application	Type
VS-0724-XY22	Mouse Anti-CTLA4 Agonistic Antibody (VS-0724-XY22)	WB, Agonistic assays	Mouse IgG1

CAT	Product Name	Application	Type
VS-0424-XY73	AbPlus™ Anti-CTLA4 Magnetic Beads (14D3)	IP, Protein Purification

CAT	Product Name	Application	Type
VS-0225-XY92	CytoStream™ Mouse Anti-CTLA4 Recombinant Antibody (clone BNI3)	FC	Mouse IgG2a, kappa
VS-0225-XY93	CytoStream™ Armenian Hamster Anti-CTLA4 Recombinant Antibody (clone UC10-4F10-11)	FC, IP	Armenian Hamster IgG1, kappa

CAT	Product Name	Application	Type
VS-0325-FY63	Human Anti-CTLA4 (clone JMW-3B3) scFv-Fc Chimera	ELISA	Human IgG1, scFv-Fc

CAT	Product Name	Application	Type
VS-0425-YC558	Recombinant Anti-CTLA4 Vesicular Antibody, EV Displayed (VS-0425-YC558)	ELISA, FC, SPR, Neut, Cell-uptake

CAT	Product Name	Application	Type
VS-0525-XY1763	Anti-CTLA4 Immunohistochemistry Kit	IHC
VS-0525-XY1764	Anti-Mouse CTLA4 Immunohistochemistry Kit	IHC

Specific Inquiry

Size:

Conjugation:

Endotoxin:

Purity:

Formats:

Isotype Switching:

Fc Engineering:

Modalities:

Add to compare

Request
Custom Production

See Our Custom Production in Action

Figure 1 Anti-HBV Recombinant Antibody (TAB-147) in SDS-PAGE

Download the full case study

Popular Products

Figure 2 Anti-CD248 Recombinant Antibody (TAB-773) in HPLC

Anti-CD248 Recombinant Antibody (Ontuxizumab) (CAT# TAB-773)
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC

Figure 2 Anti-Human CD25 Antibody (TAB-023) in HPLC

Anti-Human CD25 Recombinant Antibody (Daclizumab) (CAT# TAB-023)
Application: ELISA, Neut, IF, IP, FC, FuncS

Figure 4 Anti-CD33 Recombinant Antibody (TAB-756) in SEC-HPLC

Anti-CD33 Recombinant Antibody (TAB-756) (CAT# TAB-756)
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC

Figure 3 Llama Anti-human LC-kappa VHH Single Domain Antibody (VHH-His-Cys) (NABG-118-UN) in DB

Llama Anti-human LC-kappa VHH Single Domain Antibody [Biotin] (CAT# NABG-118)
Application: ELISA, WB, BLI, SPR

Figure 3 Anti-Human VEGF Antibody Fab Fragment (TP-104CL) in DB

Human Anti-Human VEGF Recombinant Antibody; Fab Fragment (TP-104CL) (CAT# TP-104CL)
Application:

Figure 2 Mouse Anti-DOTA Recombinant Antibody (PABW-133) in HPLC

Mouse Anti-DOTA Recombinant Antibody (clone 2D12.5) (CAT# PABW-133)
Application: ELISA

Figure 5 Recombinant Human Anti-EBV BLLF1 Antibody (PABZ-138) in DB

Recombinant Human Anti-EBV BLLF1 Antibody (72A1) (CAT# PABZ-138)
Application: Neut, ELISA

Figure 5 Anti-Human CA9 Recombinant Antibody (TAB-1458CL) in DB

Anti-Human CA9 Recombinant Antibody (MSC3) (CAT# TAB-1458CL)
Application: FC

Figure 2 Anti-CD3 Recombinant Antibody (TAB-0416CL-F(E)) in HPLC

Mouse Anti-CD3 Recombinant Antibody Fab Fragment (TAB-0416CL-F(E)) (CAT# TAB-0416CL-F(E))
Application: IB, ELISA, FC, FuncS

Figure 6 Recombinant Human Anti-H3N2 HA Antibody (F045-092) (PABC-233) in DB

Recombinant Human Anti-H3N2 HA Antibody (F045-092) (CAT# PABC-233)
Application: Neut

Figure 3 Anti-CD33 Antibody (TAB-119LC) in DB

Mouse Anti-CD33 Recombinant Antibody (TAB-119LC) (CAT# TAB-119LC)
Application: ELISA, IF, RIA

Figure 2 Anti-Human TfR Recombinant Antibody Fab Fragment (TAB-611CT-F(E)) in WB

Humanized Anti-TFRC Recombinant Antibody; Fab Fragment (TAB-611CT-F(E)) (CAT# TAB-611CT-F(E))
Application: ELISA

Figure 3 Anti-Human ERBB2 Recombinant Antibody (TAB-558MZ) in WB

Human Anti-NOTCH3 Recombinant Antibody (TAB-558MZ) (CAT# TAB-558MZ)
Application: Inhib, Neut

Figure 6 Anti-SARS-CoV S Therapeutic Antibody (CR3022) (MRO-1214LC) in Dot Blot

Anti-SARS-CoV S Recombinant Antibody (MRO-1214LC) (CAT# MRO-1214LC)
Application: Neut, ELISA

Figure 2 Recombinant Rat Anti-NGF Antibody (PABX-146) in SDS-PAGE

Recombinant Rat Anti-NGF Antibody (αD11) (CAT# PABX-146)
Application: Neut, FC, FuncS

Figure 2 Human Anti-IL15 Recombinant Antibody (HPAB-0238-YC) in WB

Human Anti-IL15 Recombinant Antibody (HPAB-0238-YC) (CAT# HPAB-0238-YC)
Application: ELISA, FC, Inhib, FuncS

Figure 5 Mouse Anti-FAP Recombinant Antibody (HPAB-0171-CN) in ELISA

Mouse Anti-FAP Recombinant Antibody (HPAB-0171-CN) (CAT# HPAB-0171-CN)
Application: ELISA

Figure 2 Human Anti-CA19-9 Recombinant Antibody; Fab Fragment (HPAB-0038-WJ-F(E)) in HPLC

Human Anti-CA19-9 Recombinant Antibody Fab Fragment (HPAB-0038-WJ-F(E)) (CAT# HPAB-0038-WJ-F(E))
Application: ELISA

Figure 2 Anti-FAP Antibody in ELISA.

Mouse Anti-FAP Recombinant Antibody (clone F19) (CAT# HPAB-A1368-YJ)
Application: ELISA, FuncS, RIA, IP, IF, IHC, IA, Block

Figure 1 Mouse Anti-PIK3CA H1047R Recombinant Antibody (MOB-0202F) in IHC

Mouse Anti-PIK3CA H1047R Recombinant Antibody (MOB-0202F) (CAT# MOB-0202F)
Application: IHC-P, IF

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.